Shaperon is a clinical stage biotech company developing novel inflammasome inhibitors. It was founded in 2008 and had a successful IPO in October 2022 in Korea. Its unique mechanism of action of GPCR19-P2X7 modulation suppresses a broad spectrum of inflammatory cytokines including IL-1β, IL-18, IL-6, and TNF-α, etc. by controlling both priming and activation phase of inflammasome. With this unique and novel modality which is best suited to address complex immune-mediated inflammatory disorders, Shaperon is currently developing multiple clinical programs in atopic dermatitis, cytokine release syndrome, and Alzheimer’s disease. In addition to inflammasome R&D programs, Shaperon has anti-cancer nanobody bispecifics and trispecific therapeutics. Shaperon’s proprietary immunized nanobody libraries combined with high throughput screening and in vitro/in vivo system enable us to fast forward the realization of advantages of nanobodies over conventional antibody-based medicines. We are currently developing multi-valent, multi-specific nanobodies in multiple delivery forms in oncology and viral infection diseases. Its leading bispecific nanobody pipeline targets CD47xPD-L1.